Hypertension prescribing varies from guidelines
1
PharmacoEconomics & Outcomes News 305 - 24 Mar 2001 ■ Prescribing patterns in the treatment of hypertension do not follow US guideline recommendations, according to the results of a US- based Delphi panel study. * Although JNC-VI ** guidelines recommend initial pharmacotherapy with a diuretic or β-blocker in patients with mild-to-moderate hypertension, 7 of 10 physicians surveyed reported prescribing other agents for initial therapy. Also, whereas the guidelines recommend monotherapy for initial treatment, 8 of 10 physicians reported that only 5–50% of patients were receiving a particular medication as monotherapy. Overall, the study authors estimated that the physicians showed 60% compliance with the JNC-VI recommendations regarding choice of initial drug therapy. * The study was sponsored by Boehringer Ingelheim Pharmaceuticals Inc., US. ** the Sixth Report of the US Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Richter A, et al. Delphi panel study of current hypertension treatment patterns. Clinical Therapeutics 23: 160-167, Jan 2001 800830290 1 PharmacoEconomics & Outcomes News 24 Mar 2001 No. 305 1173-5503/10/0305-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Hypertension prescribing varies from guidelines
PharmacoEconomics & Outcomes News 305 - 24 Mar 2001
■ Prescribing patterns in the treatment ofhypertension do not follow US guidelinerecommendations, according to the results of a US-based Delphi panel study.* Although JNC-VI**
guidelines recommend initial pharmacotherapy with adiuretic or β-blocker in patients with mild-to-moderatehypertension, 7 of 10 physicians surveyed reportedprescribing other agents for initial therapy. Also,whereas the guidelines recommend monotherapy forinitial treatment, 8 of 10 physicians reported that only5–50% of patients were receiving a particularmedication as monotherapy. Overall, the studyauthors estimated that the physicians showed 60%compliance with the JNC-VI recommendationsregarding choice of initial drug therapy.* The study was sponsored by Boehringer IngelheimPharmaceuticals Inc., US.** the Sixth Report of the US Joint National Committee onPrevention, Detection, Evaluation, and Treatment of High BloodPressure
Richter A, et al. Delphi panel study of current hypertension treatment patterns.Clinical Therapeutics 23: 160-167, Jan 2001 800830290
1
PharmacoEconomics & Outcomes News 24 Mar 2001 No. 3051173-5503/10/0305-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
